Physician profile
Jay Rosenberg
NPI 1609804848
$65,542.60
in general payments reported to CMS, 2019-2025
38 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $656 · 2021: $806 · 2022: $7,739 · 2023: $1,185 · 2024: $1,182 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $40,630.23 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $10,592.91 | 2019 | |
| Horizon Therapeutics Plc | $7,603.10 | 2022-2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $1,110.04 | 2019-2023 | |
| Biogen, INC. | $1,106.80 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $536.73 | 2019-2024 | Ultomiris |
| Genentech, INC. | $445.04 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Sunovion Pharmaceuticals INC. | $431.10 | 2019-2020 | |
| Amgen INC. | $401.52 | 2019-2024 | Uplizna |
| Neurocrine Biosciences, INC. | $318.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $217.96 | 2019 | |
| Allergan, INC. | $214.55 | 2019 | |
| Celgene Corporation | $204.03 | 2019-2023 | Zeposia |
| Boston Scientific Corporation | $198.39 | 2019-2023 | |
| Axogen | $192.78 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $169.56 | 2021 | |
| Medtronic, INC. | $164.22 | 2024 | Mazor X System |
| Tg Therapeutics, INC. | $124.99 | 2024 | |
| Banner Life Sciences, LLC | $116.47 | 2021-2023 | |
| Adamas Pharmaceuticals, INC. | $109.82 | 2019 | |
| Merz North America, INC. | $63.13 | 2019 | |
| Genentech USA, INC. | $60.62 | 2021-2023 | Ocrevus, Enspryng |
| Medtronic Vascular, INC. | $57.62 | 2019 | |
| Livanova USA, INC. | $55.59 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acorda Therapeutics, INC | $53.75 | 2019 | |
| Amneal Pharmaceuticals LLC | $53.64 | 2019 | |
| Greenwich Biosciences, INC. | $50.89 | 2019 | |
| Abbvie INC. | $32.59 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $30.95 | 2019 | |
| Acadia Pharmaceuticals INC | $30.70 | 2019 | |
| Lilly USA, LLC | $30.06 | 2019 | |
| Portola Pharmaceuticals, LLC | $27.56 | 2019 | |
| Lundbeck LLC | $22.64 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.51 | 2019 | |
| Kyowa Kirin, INC. | $19.57 | 2019 | |
| Medtronic USA, INC. | $16.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.73 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.